Cyemptive Technologies Announces Liaison Partnership with Netherlands-based Partnership for Cyber Security Innovation
9.7.2024 08:00:00 EEST | Business Wire | Press release
Cyemptive Technologies, an award-winning provider of pre-emptive cybersecurity solutions for business and government, today announced that it has entered into a liaison partnership with Partnership for Cyber Security Innovation (PCSI) in the Netherlands.
PCSI is a public/private sector network of government bodies, research institutes, corporations and startups/scaleups and designed to make Dutch society more secure and resilient against future cyber-attacks. Its major partners include leading public and private sector organizations such as ABN Amro, Achmea, ASML, ING, Dutch Tax & Customs Administration and TNO.
“I am excited that Cyemptive joins the PCSI ecosystem as a Liaison Partner,” said Reinder Wolthuis, Program Manager PCSI. “PCSI is about innovation and collaboration. As a relatively young and innovative cybersecurity company and Cyemptive’s mission to transform the cybersecurity industry to a fully proactive approach, Cyemptive is a natural fit for PCSI.”
PCSI is an open innovation platform that aims to make Dutch society more secure and resilient against future cyber-attacks. By giving them a platform for sharing knowledge and expertise, PCSI offers its core partners a unique opportunity to develop innovative cybersecurity solutions that boost the cyber resilience of both individual companies and Dutch society in general. The innovation projects include a variety of cybersecurity challenges, from advanced detection systems to software for structuring data automatically and human-factor solutions.
“Being part of PCSI provides organizations with a platform to influence cybersecurity policies and standards,” said Rob Pike, founder and CEO of Cyemptive. “This ensures that their specific needs and concerns are considered in the development of industry regulations and guidelines.”
Cyemptive offers military-grade layers of pre-emptive cybersecurity protection that are essential add-ons for businesses to achieve cyber safety. Cyemptive’s ZeroStrike allows customers to be in command of their security by eliminating damage even from unknown attack vectors pre-zero day discovery. With Cyemptive ZeroStrike there is no need for recovery and remediation, an industry first capability.
About PCSI
Partnership for Cyber Security Innovation makes a vital contribution to a secure and resilient digital society through innovation in cybersecurity. Within PCSI, applicable, innovative cybersecurity solutions are developed that allow stakeholders in Dutch society to protect themselves against the cyber-attacks of tomorrow. By working together closely via an innovative ecosystem, PCSI partners connect applied research, current data and issues from society in the field of cybersecurity in a unique way.
About Cyemptive Technologies
Headquartered in Seattle, Wash., Cyemptive has been on a mission to make large organizations cyber safe since 2014. Today, Cyemptive’s award-winning software, services and support are used by businesses and government entities worldwide. It is the winner of the Department of Homeland Security’s Border Security Technology Consortium (BSTC) competition for most innovative border security-related solution in the market, as well as 11 ‘ASTORS’ Homeland Security Awards from American Security Today in 2023 and received 10 awards in 2022 – more than any other company. Cyemptive’s leadership team is comprised of executives from several of the world’s most powerful technology and security organizations, including the former CIO of Microsoft and the former Chief Computer Architect for the National Security Agency. More information about Cyemptive Technologies is available at www.cyemptive.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240707748050/en/
Contacts
Belinda Young
BYPR
+1 206-932-3145
byoung@bypr.com
Rob Pike
Cyemptive Technologies
+1 425-341-9800
info@cyemptive.com
Wessel Graatsma
Vice President Cybersecurity Solutions Europe
+31 6 4868 2748
wgraatsma@cyemptive.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom